Drug Trial Radar · NCT06697197
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
286
Planned (sponsor's estimate)
Start
Feb 17, 2025
Primary completion
Jan 4, 2029
Study completion Jan 5, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate the safety and efficacy of BMS-986482 alone and as combination therapy in participants with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
BMS-986482Drug
Specified dose on specified days
PumitamigDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)Time frame: Up to 135 days post last treatment visit
- Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0Time frame: Up to 135 days post last treatment visit
- Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0Time frame: Up to Day 28
- Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0Time frame: Up to 135 days post last treatment visit
- Number of deaths as assessed by NCI-CTCAE v5.0Time frame: Through study completion (Up to 4 years)
Locations
21 sites in 9 countries. Site status is shown where the registry gives one.
University of California, Irvine (UCI) Health - UC Irvine Medical Center
Irvine, California · Recruiting
The Angeles Clinic and Research Institute - West Los Angeles Office
Los Angeles, California · Recruiting
Local Institution - 0008
Aurora, Colorado · Not yet recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Northwell Health/ RJ Zuckerberg Cancer Center
Lake Success, New York · Recruiting
Levine Cancer Institute
Charlotte, North Carolina · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
UZ Gent
Ghent, Oost-Vlaanderen, Belgium · Recruiting
Rigshospitalet
Copenhagen, Capital Region, Denmark · Recruiting
Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone
Marseille, Bouches-du-Rhône, France · Recruiting
Gustave Roussy
Villejuif, Paris, France · Recruiting
General Hospital of Athens "Laiko"
Athens, Attikí, Greece · Recruiting
Papageorgiou General Hospital of Thessaloniki
Thessaloniki, Thessaloníki, Greece · Recruiting
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy · Recruiting
Istituto Clinico Humanitas
Rozzano, Milano, Italy · Recruiting
Erasmus Medisch Centrum
Rotterdam, Netherlands · Recruiting
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL)
Amsterdam, North Holland, Netherlands · Recruiting
Hospital Universitario HM Sanchinarro
Madrid, Spain · Recruiting
Hospital Universitari Vall d'Hebron
Barcelona, Barcelona [Barcelona], Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Navarre, Spain · Recruiting
Karolinska Universitetssjukhuset Solna
Solna, Stockholms Län [se-01], Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.